• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PD-L1表达和肿瘤浸润免疫细胞预示胰腺导管腺癌和腺鳞癌预后不良。

The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.

作者信息

Zhang Zhiwei, Xiong Qunli, Xu Yongfeng, Cai Xuebin, Zhang Lisha, Zhu Qing

机构信息

Abdominal Oncology Ward, Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China.

出版信息

J Clin Med. 2023 Feb 9;12(4):1398. doi: 10.3390/jcm12041398.

DOI:10.3390/jcm12041398
PMID:36835933
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9965576/
Abstract

The tumor microenvironment (TME) plays a vital role in the development, progression, and metastasis of pancreatic cancer (PC). The composition of the TME and its potential prognostic value remains to be fully understood, especially in adenosquamous carcinoma of pancreas (ASCP) patients. Immunohistochemistry was used to explore the clinical significance of CD3, CD4, CD8, FoxP3, and PD-L1 expression within the TME and to identify correlations with the prognosis of PC in a series of 29 patients with ASCP and 54 patients with pancreatic ductal adenocarcinoma (PDAC). Data from the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) were accessed to obtain the scRNA-seq data and transcriptome profiles. Seurat was used to process the scRNA-seq data, and CellChat was used to analyze cell-cell communication. CIBERSORT was used to approximate the constitution of tumor-infiltrating immune cell (TICs) profiles. Higher levels of PD-L1 were linked with a shorter overall survival in ASCP ( = 0.0007) and PDAC ( = 0.0594). A higher expression of CD3+ and CD8+ T-cell infiltration was significantly correlated with a better prognosis in PC. By influencing the composition of tumor-infiltrating immune cells (TICs), high levels of PD-L1 expression are linked with a shorter overall survival in ASCP and PDAC.

摘要

肿瘤微环境(TME)在胰腺癌(PC)的发生、发展和转移中起着至关重要的作用。TME的组成及其潜在的预后价值仍有待充分了解,尤其是在胰腺腺鳞癌(ASCP)患者中。采用免疫组织化学方法探讨29例ASCP患者和54例胰腺导管腺癌(PDAC)患者TME中CD3、CD4、CD8、FoxP3和PD-L1表达的临床意义,并确定其与PC预后的相关性。从基因表达综合数据库(GEO)和癌症基因组图谱(TCGA)获取数据,以获得单细胞RNA测序(scRNA-seq)数据和转录组图谱。使用Seurat处理scRNA-seq数据,使用CellChat分析细胞间通讯。使用CIBERSORT估算肿瘤浸润免疫细胞(TICs)图谱的组成。在ASCP(P = 0.0007)和PDAC(P = 0.0594)中,较高水平的PD-L1与较短的总生存期相关。CD3+和CD8+ T细胞浸润的高表达与PC的较好预后显著相关。通过影响肿瘤浸润免疫细胞(TICs)的组成,高水平的PD-L1表达与ASCP和PDAC较短的总生存期相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/be4499f5ca20/jcm-12-01398-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/b51efe221cb4/jcm-12-01398-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/60ed572572db/jcm-12-01398-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/1c9bdd5a8ee1/jcm-12-01398-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/be83692e5e6e/jcm-12-01398-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/e8e8dfb08a44/jcm-12-01398-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/be4499f5ca20/jcm-12-01398-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/b51efe221cb4/jcm-12-01398-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/60ed572572db/jcm-12-01398-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/1c9bdd5a8ee1/jcm-12-01398-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/be83692e5e6e/jcm-12-01398-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/e8e8dfb08a44/jcm-12-01398-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/19a9/9965576/be4499f5ca20/jcm-12-01398-g006.jpg

相似文献

1
The PD-L1 Expression and Tumor-Infiltrating Immune Cells Predict an Unfavorable Prognosis in Pancreatic Ductal Adenocarcinoma and Adenosquamous Carcinoma.PD-L1表达和肿瘤浸润免疫细胞预示胰腺导管腺癌和腺鳞癌预后不良。
J Clin Med. 2023 Feb 9;12(4):1398. doi: 10.3390/jcm12041398.
2
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.单细胞 RNA 测序揭示了抗 CD47 靶向治疗诱导的胰腺癌肿瘤浸润免疫细胞的区室重排。
J Hematol Oncol. 2019 Nov 27;12(1):124. doi: 10.1186/s13045-019-0822-6.
3
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.PD-L1 是胰腺导管腺癌(PDAC)中癌症 FOXP3 的直接靶点,联合使用抗 PD-L1 和 CCL5 抗体的免疫疗法对 PDAC 的治疗有效。
Signal Transduct Target Ther. 2020 Apr 17;5(1):38. doi: 10.1038/s41392-020-0144-8.
4
Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma.胰腺腺鳞癌的临床特征和预后 - 与胰腺导管腺癌的配对分析。
Eur J Surg Oncol. 2021 Jul;47(7):1734-1741. doi: 10.1016/j.ejso.2021.02.011. Epub 2021 Feb 16.
5
Immunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targets.胰腺腺鳞癌中的免疫突变特征:潜在治疗靶点的探索性研究。
Expert Opin Ther Targets. 2018 May;22(5):453-461. doi: 10.1080/14728222.2018.1456530. Epub 2018 Mar 27.
6
The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.程序性细胞死亡配体1和人类白细胞抗原I类在胰腺癌中的预后影响。
Cancer Med. 2017 Jul;6(7):1614-1626. doi: 10.1002/cam4.1087. Epub 2017 Jun 10.
7
Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: study of 13 cases comparing ductal pancreatic carcinoma and review of the literature.肿瘤细胞 PD-L1 表达对伴有破骨样巨细胞的未分化(间变性)胰腺腺癌的预后有负面影响:对 13 例病例的研究比较了导管腺癌,并复习了文献。
Virchows Arch. 2020 Nov;477(5):687-696. doi: 10.1007/s00428-020-02830-8. Epub 2020 May 18.
8
A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma.一种预测胰腺导管腺癌预后并揭示免疫浸润特征的新型免疫基因组特征。
Precis Clin Med. 2022 Apr 25;5(2):pbac010. doi: 10.1093/pcmedi/pbac010. eCollection 2022 Jun.
9
Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.PD-1/PD-L1、CD8和FOXP3在胰腺导管腺癌中与促纤维增生性间质的预后价值、定位及相关性
Oncotarget. 2016 Jul 5;7(27):40992-41004. doi: 10.18632/oncotarget.10038.
10
Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌中肿瘤内和肿瘤周围浸润淋巴细胞的预后意义。
Curr Oncol. 2021 Nov 1;28(6):4367-4376. doi: 10.3390/curroncol28060371.

引用本文的文献

1
Prognostic Value of TBC1D1 and Its Relationship With the Tumor Microenvironment in Pancreatic Cancer: A Study Based on Single-Cell Sequencing.TBC1D1在胰腺癌中的预后价值及其与肿瘤微环境的关系:一项基于单细胞测序的研究
FASEB Bioadv. 2025 Jul 9;7(7):e70034. doi: 10.1096/fba.2025-00092. eCollection 2025 Jul.
2
Association of PD-L1 Expression with Lymph Node Metastasis and Clinical Stage in Ampulla of Vater Cancer: An Observational Study.壶腹癌中PD-L1表达与淋巴结转移及临床分期的相关性:一项观察性研究
Cancer Manag Res. 2025 May 13;17:965-974. doi: 10.2147/CMAR.S513961. eCollection 2025.
3
Causal role of immune cells in Hashimoto's thyroiditis: Mendelian randomization study.

本文引用的文献

1
Pancreatic Adenosquamous Carcinoma: A Rare Pathological Subtype of Pancreatic Cancer.胰腺腺鳞癌:一种罕见的胰腺癌病理亚型。
J Clin Med. 2022 Dec 14;11(24):7401. doi: 10.3390/jcm11247401.
2
The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer.微生物组衍生代谢物 TMAO 驱动免疫激活,并增强对胰腺癌免疫检查点阻断的反应。
Sci Immunol. 2022 Sep 9;7(75):eabn0704. doi: 10.1126/sciimmunol.abn0704.
3
Macrophages as tools and targets in cancer therapy.巨噬细胞作为癌症治疗的工具和靶点。
免疫细胞在桥本甲状腺炎中的因果作用:孟德尔随机化研究。
Front Endocrinol (Lausanne). 2024 May 13;15:1352616. doi: 10.3389/fendo.2024.1352616. eCollection 2024.
4
PD-L1 expression in pancreaticobiliary adenosquamous carcinoma: a single-institution case series.胰腺胆管腺鳞癌中PD-L1的表达:一项单机构病例系列研究。
J Gastrointest Oncol. 2024 Apr 30;15(2):768-779. doi: 10.21037/jgo-24-9. Epub 2024 Apr 25.
Nat Rev Drug Discov. 2022 Nov;21(11):799-820. doi: 10.1038/s41573-022-00520-5. Epub 2022 Aug 16.
4
Immunogenic Cell Death and Role of Nanomaterials Serving as Therapeutic Vaccine for Personalized Cancer Immunotherapy.免疫原性细胞死亡与作为个性化癌症免疫治疗的治疗性疫苗的纳米材料的作用。
Front Immunol. 2022 Jun 30;13:925290. doi: 10.3389/fimmu.2022.925290. eCollection 2022.
5
Cancer statistics, 2022.癌症统计数据,2022 年。
CA Cancer J Clin. 2022 Jan;72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12.
6
Single-cell transcriptomics reveals heterogeneous progression and EGFR activation in pancreatic adenosquamous carcinoma.单细胞转录组学揭示了胰腺腺鳞癌的异质性进展和 EGFR 激活。
Int J Biol Sci. 2021 Jun 22;17(10):2590-2605. doi: 10.7150/ijbs.58886. eCollection 2021.
7
The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.肠道微生物组与胃肠道癌症抗 PD-1/PD-L1 免疫治疗的临床反应相关。
Cancer Immunol Res. 2020 Oct;8(10):1251-1261. doi: 10.1158/2326-6066.CIR-19-1014. Epub 2020 Aug 27.
8
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.胰腺癌中肿瘤浸润淋巴细胞的预后价值:系统评价和荟萃分析。
Eur J Cancer. 2020 Jun;132:71-84. doi: 10.1016/j.ejca.2020.03.013. Epub 2020 Apr 22.
9
PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.PD-L1 是胰腺导管腺癌(PDAC)中癌症 FOXP3 的直接靶点,联合使用抗 PD-L1 和 CCL5 抗体的免疫疗法对 PDAC 的治疗有效。
Signal Transduct Target Ther. 2020 Apr 17;5(1):38. doi: 10.1038/s41392-020-0144-8.
10
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.免疫原性细胞死亡的定义、检测及解读的共识指南。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000337.